{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-21-000045","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.829087+00:00","generated_at":"2026-06-28T16:36:50.467115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Rad Q3 revenue $747M (+15.4% YoY); non-GAAP EPS $3.71; raises FY21 guidance","bullets":["Life Science segment revenue $373.5M (+15.3% YoY); Clinical Diagnostics $372.2M (+15.5% YoY).","GAAP net income $3.93B ($129.96 diluted EPS) driven by $4.87B unrealized gain on Sartorius equity.","Non-GAAP net income $112.2M ($3.71 diluted EPS) vs $90.3M ($3.00) a year ago.","Full-year 2021 guidance: non-GAAP currency-neutral revenue growth 12-13%; operating margin ~19.5%.","Gross margin improved to 58.6% from 56.7%; operating margin 21.0% vs 16.9%."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-21-000045","json":"https://secwatch.observer/filing/0000012208-21-000045.json","markdown":"https://secwatch.observer/filing/0000012208-21-000045.md","text":"https://secwatch.observer/filing/0000012208-21-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220821000045/0000012208-21-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220821000045/bio-20211028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T16:36:50.467115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}